Who
Tien-Li Lee
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Aardvark Therapeutics; Director, Scilex Holding.
In numbers
- Trades disclosed
- 17
- Buys
- 6
- Sells
- 0
- Bought
- $623K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 17 Jan 2023
- Last trade
- 9 Feb 2026
- Last filed
- 11 Feb 2026
Companies traded
Activity over time
1 Feb 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Feb 2026filed 11 Feb 2026 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —203,851 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —203,851 at $0.00 | filing |
| 11 Dec 2025filed 12 Dec 2025 | AARD Aardvark TherapeuticsBiotechnology | SEC FORM 4 Bought | $101K7,000 at $14.49 | filing |
| 15 Oct 2025filed 16 Oct 2025 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,229 at $0.00 | filing |
| 15 Oct 2025filed 16 Oct 2025 | AARD Aardvark TherapeuticsBiotechnology | SEC FORM 4 Code M | $5,2111,229 at $4.24 | filing |
| 15 Sep 2025filed 16 Sep 2025 | AARD Aardvark TherapeuticsBiotechnology | SEC FORM 4 Bought | $62K6,500 at $9.51 | filing |
| 15 Sep 2025filed 16 Sep 2025 | AARD Aardvark TherapeuticsBiotechnology | SEC FORM 4 Bought | $35K3,500 at $9.94 | filing |
| 12 Sep 2025filed 12 Sep 2025 | AARD Aardvark TherapeuticsBiotechnology | SEC FORM 4 Bought | $43K5,000 at $8.50 | filing |
| 11 Sep 2025filed 12 Sep 2025 | AARD Aardvark TherapeuticsBiotechnology | SEC FORM 4 Bought | $47K6,000 at $7.82 | filing |
| 10 Sep 2025filed 12 Sep 2025 | AARD Aardvark TherapeuticsBiotechnology | SEC FORM 4 Bought | $71K9,000 at $7.91 | filing |
| 28 Aug 2025filed 29 Aug 2025 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,209 at $0.00 | filing |
| 28 Aug 2025filed 29 Aug 2025 | AARD Aardvark TherapeuticsBiotechnology | SEC FORM 4 Code M | $73K17,209 at $4.24 | filing |
| 11 Jun 2025filed 13 Jun 2025 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —549,534 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —350,002 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | AARD Aardvark TherapeuticsBiotechnology | SEC FORM 4 Code C | —41,303 | filing |
| 14 Feb 2025filed 19 Feb 2025 | AARD Aardvark TherapeuticsBiotechnology | SEC FORM 4 Bought | $265K16,542 at $16.00 | filing |
| 17 Jan 2023filed 17 Jan 2023 | SCLX Scilex Holdingoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
News
Aardvark Therapeutics (NASDAQ:AARD) Given New $4.00 Price Target at HC WainwrightAARD · dailypolitical.com · 20 Oct 2026Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Hub Group, Inc. (NASDAQ: HUBG); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your BehalfAARD · mykxlg.com · 19 Oct 2026
0 headlines in the last 90 days name Tien-Li Lee; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.